Entries by CURC

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. With Dr. Neal Shore

/in /by

Optimal sequencing strategies for approved agents in metastatic castration-resistant prostate cancer (mCRPC) are unclear. Retrospective clinical studies suggest cross-resistance between specific therapies. This review assesses treatment decisions for mCRPC. Increased use of chemohormonal therapy in castration-sensitive disease may affect subsequent treatment decisions in mCRPC. Initial abiraterone or enzalutamide treatment may result in cross-resistance for subsequent […]

Cutting-edge trials: treatments for newly diagnosed mHSPC patients

/in /by

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][su_youtube url=”https://youtu.be/GpQBnWjJDR8″][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]

Recognizing Symptom Burden in Advanced Prostate Cancer: a Global Patient and Caregiver Survey

/in /by

As posted on October 5th by www.clinical-genitourinary-cancer.com. With Dr. Neal Shore. Introduction Prostate cancer is the second most common malignancy in men worldwide, with an estimated 1.1 million men across the world diagnosed in 2012, and the fifth leading cause of cancer-related death in men, with 307,000 deaths reported worldwide in 2012.1 Prostate cancer is […]

Antiandrogen’s role may extend to non-metastatic castration-resistant prostate cancer (CRPC).

/in /by

As posted on October 4th by Urology Times. With Dr. Neal Shore. by Cheryl Guttman Krader Top-line results from the phase III PROSPER trial support a potential role for enzalutamide (XTANDI) as treatment for non-metastatic castration-resistant prostate cancer (CRPC). The efficacy analysis showed that the study met its primary endpoint by demonstrating that the combination […]